↓ Skip to main content

TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES

Overview of attention for article published in Arquivos de Gastroenterologia, June 2018
Altmetric Badge

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
44 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES
Published in
Arquivos de Gastroenterologia, June 2018
DOI 10.1590/s0004-2803.201800000-36
Pubmed ID
Authors

Fábio Vieira TEIXEIRA, Adérson Omar Mourão Cintra DAMIÃO, Paulo Gustavo KOTZE

Abstract

Janus kinases inhibitors have already been incorporated into the management of immune-mediated diseases, such as rheumatoid arthritis, and are being investigated for the treatment of psoriasis and inflammatory bowel diseases, both ulcerative colitis and Crohn's disease. Tofacitinib is an oral small-molecule drug that inhibits Janus kinases 1, Janus kinases 3, and, to a lesser extent, Janus kinases 2. This inhibition ends up blocking signals for several inflammatory cytokines that are involved in the pathogenesis of inflammatory bowel diseases and play a role in many immune signaling routes, including lymphocyte activation, function, and proliferation. We report a patient with active ulcerative colitis with primary non-response to three biologics (infliximab, adalimumab and vedolizumab), with different mechanisms of action, who refused surgical treatment and had a favorable response to tofacitinib with clinical and endoscopic remission. No adverse events were observed with the use of the agent. This case illustrates the difficulties we may face regarding the identification of the expression of proper mechanism of action involved in the pathogenesis of ulcerative colitis patients and the importance of having another treatment option with different mechanism of action, like tofacitinib.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 11 25%
Student > Ph. D. Student 7 16%
Student > Master 5 11%
Other 2 5%
Student > Bachelor 2 5%
Other 4 9%
Unknown 13 30%
Readers by discipline Count As %
Medicine and Dentistry 19 43%
Computer Science 3 7%
Nursing and Health Professions 1 2%
Psychology 1 2%
Agricultural and Biological Sciences 1 2%
Other 1 2%
Unknown 18 41%